Invasive Pneumococcal Disease in High-risk Children: A 10-Year Retrospective Study.
Journal
The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858
Informations de publication
Date de publication:
01 01 2023
01 01 2023
Historique:
pubmed:
1
12
2022
medline:
15
12
2022
entrez:
30
11
2022
Statut:
ppublish
Résumé
Despite the availability of conjugate pneumococcal vaccines, children with high-risk conditions remain vulnerable to invasive pneumococcal disease (IPD). This study sought to describe IPD prevalence, vaccination and outcomes among high-risk children. We used International Classification of Disease10 discharge and microbiology codes to identify patients hospitalized for IPD at a large pediatric hospital from January 1, 2009, to December 31, 2018. Patients were considered high-risk if they had: primary immunodeficiency, asplenia, transplant, active malignancy, sickle cell disease, cochlear implant, nephrotic syndrome, chronic lung disease, cerebrospinal fluid leak, HIV or used immunosuppressive therapy. In total 94 high-risk patients were hospitalized for IPD. The most common high-risk conditions included malignancy (n = 33, 35%), solid-organ or bone marrow transplant (n = 17, 18%) and sickle cell disease (n = 14, 15%). Bacteremia was the most common presentation (n = 81, 86%) followed by pneumonia (n = 23, 25%) and meningitis (n = 9, 10%). No deaths occurred. Of 66 patients with known pneumococcal vaccination status, 15 (23%) were unvaccinated, and 51 (77%) received at least one dose of a pneumococcal vaccine; 20 received all four recommended pneumococcal conjugate vaccine (PCV) doses. Only three children received PPSV23. Of 20 children with no or partial (<3 doses) immunization, 70% (14) of IPD episodes were due to vaccine-preventable serotypes. Of 66 known IPD serotypes, 17% (n = 11) were covered by PCV13, 39% (n = 26) were covered by PPSV23 and 39% (n = 26) were nonvaccine serotype. Despite the availability of effective pneumococcal vaccines, IPD persists among children with high-risk conditions. Improving PCV13 and PPSV23 vaccination could significantly reduce IPD; most episodes were due to vaccine-preventable serotypes in incompletely immunized patients.
Sections du résumé
BACKGROUND
Despite the availability of conjugate pneumococcal vaccines, children with high-risk conditions remain vulnerable to invasive pneumococcal disease (IPD). This study sought to describe IPD prevalence, vaccination and outcomes among high-risk children.
METHODS
We used International Classification of Disease10 discharge and microbiology codes to identify patients hospitalized for IPD at a large pediatric hospital from January 1, 2009, to December 31, 2018. Patients were considered high-risk if they had: primary immunodeficiency, asplenia, transplant, active malignancy, sickle cell disease, cochlear implant, nephrotic syndrome, chronic lung disease, cerebrospinal fluid leak, HIV or used immunosuppressive therapy.
RESULTS
In total 94 high-risk patients were hospitalized for IPD. The most common high-risk conditions included malignancy (n = 33, 35%), solid-organ or bone marrow transplant (n = 17, 18%) and sickle cell disease (n = 14, 15%). Bacteremia was the most common presentation (n = 81, 86%) followed by pneumonia (n = 23, 25%) and meningitis (n = 9, 10%). No deaths occurred. Of 66 patients with known pneumococcal vaccination status, 15 (23%) were unvaccinated, and 51 (77%) received at least one dose of a pneumococcal vaccine; 20 received all four recommended pneumococcal conjugate vaccine (PCV) doses. Only three children received PPSV23. Of 20 children with no or partial (<3 doses) immunization, 70% (14) of IPD episodes were due to vaccine-preventable serotypes. Of 66 known IPD serotypes, 17% (n = 11) were covered by PCV13, 39% (n = 26) were covered by PPSV23 and 39% (n = 26) were nonvaccine serotype.
CONCLUSIONS
Despite the availability of effective pneumococcal vaccines, IPD persists among children with high-risk conditions. Improving PCV13 and PPSV23 vaccination could significantly reduce IPD; most episodes were due to vaccine-preventable serotypes in incompletely immunized patients.
Identifiants
pubmed: 36450100
doi: 10.1097/INF.0000000000003748
pii: 00006454-202301000-00020
doi:
Substances chimiques
Pneumococcal Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
74-81Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
S.M. is the co-PI on an investigator led grant from Pfizer, has served on ad hoc advisory groups with Pfizer and Sanofi Pasteur, has received speaker fees from GSK as well as funding for an unrestricted education event, and speaker fees from Johnson and Johnson China, all of which are unrelated to the topic of this paper. A.M. has funding for investigator-initiated grants from Pfizer and Merck and has received honoraria for participation on advisory boards from Pfizer, Merck, and GSK, all of which were unrelated to this study. The other authors have no conflicts of interest to disclose.
Références
WHO. Pneumococcal conjugate vaccine for childhood immunization--WHO position paper. Wkly Epidemiol Rec. 2007;82:93104.
Government of Canada HC. Invasive Pneumococcal Disease. 2021. Available at: https://www.canada.ca/en/public-health/services/immunization/vaccine-preventable-diseases/invasive-pneumococcal-disease/health-professionals.html#shr-pg0 . Accessed September 26, 2021.
Hjuler T, Wohlfahrt J, Staum Kaltoft M, et al. Risks of invasive pneumococcal disease in children with underlying chronic diseases. Pediatrics. 2008;122:e26–e32.
Modlin J, et al. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000;49:1–35.
Schutze GE, Mason EO Jr, Barson WJ, et al. Invasive pneumococcal infections in children with asplenia. Pediatr Infect Dis J. 2002;21:278–282.
Wong A, Marrie TJ, Garg S, et al.; SPAT Group. Increased risk of invasive pneumococcal disease in haematological and solid-organ malignancies. Epidemiol Infect. 2010;138:1804–1810.
Robinson KA, Baughman W, Rothrock G, et al.; Active Bacterial Core Surveillance (ABCs)/Emerging Infections Program Network. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA. 2001;285:1729–1735.
King MD, Whitney CG, Parekh F, et al.; Active Bacterial Core Surveillance Team/Emerging Infections Program Network. Recurrent invasive pneumococcal disease: a population-based assessment. Clin Infect Dis. 2003;37:1029–1036.
Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis. 2005;5:83–93.
National.Advisory.Committee.on.Immunization.(NACI). Vaccination of Specific Populations. The Public Health Agency of Canada (PHAC). 2020. Available at: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-8-immunization-immunocompromised-persons.html . Accessed August 2020.
Bennett NM, Pilishvili T, Whitney CG, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6–18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2013;62:521–524.
Desai S, Fau - McGeer A, Fau - Quach-Thanh C, et al. Update on the use of conjugate pneumococcal vaccines in childhood: an Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)(†). (1188-4169 (Print)). Can Commun Dis Rep. 2010;36(ACS-12):1–21.
Austrian R. The quellung reaction, a neglected microbiologic technique. Mt Sinai J Med. 1976;43:699–709.
Slotved HC, Kaltoft M, Skovsted IC, et al. Simple, rapid latex agglutination test for serotyping of pneumococci (Pneumotest-Latex). J Clin Microbiol. 2004;42:2518–2522.
Shigayeva A, Rudnick W, Green K, et al.; Toronto Invasive Bacterial Diseases Network. Invasive pneumococcal disease among immunocompromised persons: implications for vaccination programs. Clin Infect Dis. 2016;62:139–147.
Zhang JY, Shang T, Ahn D, et al. How to best protect people with diabetes from the impact of SARS-CoV-2: report of the international COVID-19 and diabetes summit. J Diabetes Sci Technol. 2021;15:478–514.
Moore MR, Link-Gelles R, Schaffner W, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study. Lancet Respir Med. 2016;4:399–406.
Children THfS. Haematology/Oncology. 2021. Available at: https://www.sickkids.ca/en/care-services/clinical-departments/haematology-oncology-cancer/ . Accessed September 26, 2021.
Information CIfH. e-Statistics on organ transplants, waiting lists, and donors. Canadian Institute for Health Information. 2021. Available at: https://www.cihi.ca/en/e-statistics-on-organ-transplants-waiting-lists-and-donors . Accessed September 26, 2021.
Papsin B. In: Number of new cochlear implant patients treated annually. Morris S, ed. 2021.
Bitnun A. Number of new HIV patients treated annually at SickKids. Morris S, ed. In: The Hospital for Sick Children. 2021.
Rose MA, Christopoulou D, Myint TTH, et al. The burden of invasive pneumococcal disease in children with underlying risk factors in North America and Europe. Int J Clin Pract. 2014;68:8–19.
Harboe ZB, Thomsen RW, Riis A, et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med. 2009;6:e1000081.
Top KA, Vaudry W, Morris SK, et al. Waning vaccine immunity and vaccination /responses in children treated for acute lymphoblastic leukemia: a Canadian immunization research network study. Clin Infect Dis. 2020;71:e439–e448.
Kumar D, Humar A, Plevneshi A, et al. Invasive pneumococcal disease in solid organ transplant recipients—10-year prospective population surveillance. Am J Transplant. 2007;7:1209–1214.
Tran L, Hebert D, Dipchand A, et al. Invasive pneumococcal disease in pediatric organ transplant recipients: a high-risk population. Pediatr Transplant. 2005;9:183–186.
Waight PA, Andrews NJ, Ladhani SN, et al. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. (1474-4457 (Electronic)). Lancet Infect Dis. 2015;15:535–543.
Canada Public Health Agency of Canada. National Laboratory surveillance of invasive streptococcal disease in Canada –Annual Summary. 2017. Available at: https://www.canada.ca/en/public-health/services/publications/drugs-health-products/national-laboratory-surveillance-invasive-streptococcal-disease-annual-summary-2017.html . Accessed January, 2021.
Masomian M, Ahmad Z, Gew LA-O, et al. Development of next generation streptococcus pneumoniae vaccines conferring broad protection. Vaccines (Basel). 2020;8:132.
Demczuk WHB, Martin I, Griffith A, et al. Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010–2012. Canadian J Microbiol. 2013;59:778–788.
Richter SS, Heilmann KP, Fau - Dohrn CL, et al. Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999-2011(1.). (1080-6059 (Electronic)). Emerg Infect Dis. 2013;19:1074–1083.
Liñares J, Ardanuy C, Fau - Pallares R, et al. Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period. (1469-0691 (Electronic)). Clin Microbiol Infect. 2010;16:402–410.
Messina AF, Katz-Gaynor K, Fau - Barton T, et al. Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005. (0891-3668 (Print)). Pediatr Infect Dis J. 2007;26:461–467.
Kuster SP, Rudnick W, Shigayeva A, et al. Previous antibiotic exposure and antimicrobial resistance in invasive pneumococcal disease: results from prospective surveillance. Clin Infect Dis. 2014;59:944–952.
Song J-H, Chang H-H, Suh JY, et al. Macrolide resistance and genotypic characterization of Streptococcus pneumoniae in Asian countries: a study of the Asian Network for Surveillance of Resistant Pathogens (ANSORP). J Antimicrob Chemother. 2004;53:457–463.
Gertz RE, McEllistrem MC, Boxrud DJ, et al. Clonal distribution of invasive pneumococcal isolatesfrom children and selected adults in the United States prior to7-valent conjugate vaccine introduction. J Clin Microbiol. 2003;41:4194–4216.
Ardanuy C, Rolo D, Fenoll A, et al. Emergence of a multidrug-resistant clone (ST320) among invasive serotype 19A pneumococci in Spain. J Antimicrob Chemother. 2009;64:507–510.
Moore MR, Gertz JRE, Woodbury RL, et al. Population snapshot of emergent streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis. 2008;197:1016–1027.
Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of multidrug-resistant streptococcus pneumoniae in the United States. N Engl J Med. 2000;343:1917–1924.
Hsu KK, Shea KM, Stevenson AE, et al.; Members of the Massachusetts Department of Public Health. Underlying conditions in children with invasive pneumococcal disease in the conjugate vaccine era. Pediatr Infect Dis J. 2011;30:251–253.